Benitec - BNTC Operating Margin

Benitec - graphic logo of issuer BNTC

The operating margin and 0.00, which indicates the current level, highlight Benitec Biopharma Inc. (BNTC) management's focus on the clinical validation of gene therapy. Growth potential is based on the scalability of its unique platform for treating various rare pathologies. However, the research stage entails a complete cash burn, which precludes operating profit and the generation of free cash flow.

Benitec Biopharma (BNTC): Operating Profit Rate from 07/04/2022 to 11/19/2026

Analytical breakdowns and data insights for company Benitec Biopharma (BNTC)

- share price and consensus valuation forecast:
Fundamental company valuation:Benitec Corp, BNTC
Finished products of benitec.com

Selecting assets with a high margin of safety begins with an analysis of cost management efficiency. Operating margin measures the share of profit from the core business before taxes and interest, filtering out random market fluctuations. For Benitec Biopharma Inc. (BNTC), which focuses on the clinical validation of gene therapy, this metric reflects the cost of R&D processes. The binary nature of venture business results makes this metric an indicator of survivability. By analyzing operating margin trends, an investor can discern the real resilience of Benitec Biopharma Inc. (BNTC).

Competitor analysis

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|MGTX - Operating Profitability Margin|Operating Margin RGNX|Operating Profitability SLDB (Solid Biosciences)|Ocugen Corp - Operating Sales Margin|PACB: Return on Sales by Operating Profit|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability